Compare ACM Research Inc (ACMR) vs TransMedics Group Inc (TMDX) Price & Performance

ACMR trades at $82.42, up 3.79% today, with a neutral technical signal and bearish moving averages. Recent Q2 2026 earnings of $0.61 per share beat estimates, and revenue guidance was raised following strong order growth. The company shows robust profitability with a 14.48% net income margin and 10.56% ROE, though valuation ratios like a P/E of 37.7 appear elevated. Analyst sentiment is strongly bullish with an 80% buy rating and a $127.50 consensus price target.

The outlook is positive given earnings beats and raised guidance, but high valuation and cash flow challenges from negative operating cash flow pose risks. Upside potential exists if growth continues, yet investors face volatility from market conditions and execution risks in the competitive semiconductor equipment sector.

TransMedics Group (TMDX) trades at $87.42, down 1.12% on the day, with a bullish technical outlook from moving averages but bearish oscillators signaling potential overbought conditions. The company reported mixed Q2 2026 results, missing earnings estimates with EPS of $0.44 versus $0.50 expected, while revenue growth remains robust. Recent news highlights an ongoing investigation into fiduciary duties by directors, adding uncertainty.

The stock presents a cautious opportunity with strong analyst support (69% buy ratings) and a consensus price target of $99.57, implying upside, but risks include earnings volatility, margin pressures, and legal scrutiny. Fundamentals show solid profitability with a 22.69% net margin, though valuation multiples like P/E of 23.15 suggest premium pricing relative to historical norms.